Efficacy and safety by body weight decile in patients treated with tildrakizumab 100 mg for 28 weeks: Pooled data analysis of reSURFACE 1 and reSURFACE 2

Alan M. Menter; Zoe Draelos; Jayme Heim; Ranga Gogineni; Christopher Em Griffiths

doi:10.25251/skin.7.supp.136

Back

Shared by

Christopher Em Griffiths

Efficacy and safety by body weight decile in patients treated with tildrakizumab 100 mg for 28 weeks: Pooled data analysis of reSURFACE 1 and reSURFACE 2

Article 2023 en

Authors

AM
Alan M. Menter
ZD
Zoe Draelos
JH
Jayme Heim

Related publications

Article2025

63996 Efficacy and safety of tildrakizumab for the treatment of obese patients with moderate-to-severe plaque psoriasis: Post hoc analysis of reSURFACE 1 and reSURFACE 2

Mark Lebwohl, Andrew Blauvelt, Jerry Bagel, Ranga Gogineni, Christopher Em Griffiths

Article2019

Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.

Takuji Okusaka, Kenji Ikeda, Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang–Hyub Han, Ann‐Lii Cheng, Fabio Piscaglia, Masahiro Kobayashi, Max W. Sung, Minshan Chen, Lucjan Wyrwicz, Jung‐Hwan Yoon, Zhenggang Ren, Daniel E. Stepan, Corina E. Dutcus, Toshiyuki Tamai, Min Ren, Seiichi Hayato, Hiromitsu Kumada

Article2025

Efficacy and safety of tildrakizumab in patients with early- vs. late-onset psoriasis

April W. Armstrong, Mark Lebwohl, Akihiko Asahina, Ranga Gogineni, Christopher Em Griffiths

Article2021

Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT

Takuji Okusaka, Kenji Ikeda, Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang–Hyub Han, Ann‐Lii Cheng, Fabio Piscaglia, Masahiro Kobayashi, Max W. Sung, Minshan Chen, Lucjan Wyrwicz, Jung‐Hwan Yoon, Zhenggang Ren, Kalgi Mody, Corina E. Dutcus, Toshiyuki Tamai, Min Ren, Seiichi Hayato, Hiromitsu Kumada

Article2025

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis over 5 years in patients living with obesity

Mark Lebwohl, Jerry Bagel, Ranga Gogineni, Christopher Em Griffiths

Efficacy and safety by body weight decile in patients treated with tildrakizumab 100 mg for 28 weeks: Pooled data analysis of reSURFACE 1 and reSURFACE 2

Discussion(0)

Related publications

63996 Efficacy and safety of tildrakizumab for the treatment of obese patients with moderate-to-severe plaque psoriasis: Post hoc analysis of reSURFACE 1 and reSURFACE 2

Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.

Efficacy and safety of tildrakizumab in patients with early- vs. late-onset psoriasis

Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis over 5 years in patients living with obesity